The FDA announced that it had formally withdrawn marketing denial orders issued to Juul Labs in 2022, providing the company with the opportunity to seek authorization for its e-cigarette sales.
Rescinding the marketing denial orders does not imply a new decision on authorizing e-cigarette sales; Juul's applications are now in 'pending status' for further review.
Juul expressed appreciation for the FDA's decision and aims to engage in a science- and evidence-based process for seeking marketing authorization for its products.
[
Collection
]
[
|
...
]